BMY Bristol Myers Squibb Co

Price (delayed)

$44.03

Market cap

$89.25B

P/E Ratio

N/A

Dividend/share

$2.34

EPS

-$3.09

Enterprise value

$135.6B

Bristol Myers Squibb is an American pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, ...

Highlights
Bristol Myers Squibb's EPS has shrunk by 189% YoY and by 180% QoQ
The net income has dropped by 184% year-on-year and by 177% since the previous quarter

Key stats

What are the main financial stats of BMY
Market
Shares outstanding
2.03B
Market cap
$89.25B
Enterprise value
$135.6B
Valuations
Price to book (P/B)
5.4
Price to sales (P/S)
1.96
EV/EBIT
N/A
EV/EBITDA
33.87
EV/Sales
2.98
Earnings
Revenue
$45.53B
EBIT
-$5.86B
EBITDA
$4B
Free cash flow
$12.51B
Per share
EPS
-$3.09
Free cash flow per share
$6.19
Book value per share
$8.15
Revenue per share
$22.52
TBVPS
$22.02
Balance sheet
Total assets
$99.03B
Total liabilities
$82.48B
Debt
$55.68B
Equity
$16.49B
Working capital
$2.85B
Liquidity
Debt to equity
3.38
Current ratio
1.11
Quick ratio
0.78
Net debt/EBITDA
11.58
Margins
EBITDA margin
8.8%
Gross margin
75.7%
Net margin
-13.5%
Operating margin
-12.8%
Efficiency
Return on assets
-6.5%
Return on equity
-23%
Return on invested capital
-10.9%
Return on capital employed
-8%
Return on sales
-12.9%
Dividend
Dividend yield
5.31%
DPS
$2.34
Payout ratio
N/A

BMY stock price

How has the Bristol Myers Squibb stock price performed over time
Intraday
-0.18%
1 week
-2.02%
1 month
-7.96%
1 year
-33.82%
YTD
-14.19%
QTD
-18.81%

Financial performance

How have Bristol Myers Squibb's revenue and profit performed over time
Revenue
$45.53B
Gross profit
$34.48B
Operating income
-$5.85B
Net income
-$6.15B
Gross margin
75.7%
Net margin
-13.5%
BMY's net margin has dropped by 185% year-on-year and by 176% since the previous quarter
The net income has dropped by 184% year-on-year and by 177% since the previous quarter
The operating income has dropped by 169% since the previous quarter and by 166% year-on-year
The operating margin has dropped by 168% since the previous quarter and by 167% year-on-year

Growth

What is Bristol Myers Squibb's growth rate over time

Valuation

What is Bristol Myers Squibb stock price valuation
P/E
N/A
P/B
5.4
P/S
1.96
EV/EBIT
N/A
EV/EBITDA
33.87
EV/Sales
2.98
Bristol Myers Squibb's EPS has shrunk by 189% YoY and by 180% QoQ
Bristol Myers Squibb's equity has decreased by 48% YoY and by 44% from the previous quarter
BMY's P/B is 35% above its 5-year quarterly average of 4.0 and 17% above its last 4 quarters average of 4.6
The price to sales (P/S) is 39% less than the 5-year quarterly average of 3.2 and 25% less than the last 4 quarters average of 2.6

Efficiency

How efficient is Bristol Myers Squibb business performance
The ROE has plunged by 187% from the previous quarter
Bristol Myers Squibb's ROA has plunged by 187% YoY and by 176% from the previous quarter
Bristol Myers Squibb's return on sales has shrunk by 169% QoQ and by 168% YoY
BMY's return on invested capital has dropped by 165% since the previous quarter and by 163% year-on-year

Dividends

What is BMY's dividend history
DPS
$2.34
Dividend yield
5.31%
Payout ratio
N/A
Recent dividends

Financial health

How did Bristol Myers Squibb financials performed over time
BMY's total assets is 20% greater than its total liabilities
The total liabilities has increased by 32% year-on-year and by 26% since the previous quarter
The quick ratio has decreased by 25% QoQ and by 23% YoY
The company's debt to equity has surged by 184% YoY and by 150% QoQ
Bristol Myers Squibb's equity has decreased by 48% YoY and by 44% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.